Only in Titles

Search results for: Caspase-3 Inhibitor Z-DEVD-FMK ; Appearance Liquid

paperclip

#20696207   2010/08/07 To Up

Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells.

The nicotinamide phosphoribosyltransferase (Nampt) inhibitor APO866 depletes intracellular nicotinamide adenine dinucleotide (NAD(+)) and shows promising anticancer activity in preclinical studies. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) binds to plasma membrane receptors DR4 and DR5 and induces apoptosis via caspase-8 and -10. Here we have explored the interaction between APO866 and TRAIL in leukemia cell lines and in primary B-cell chronic lymphocytic leukemia cells.
Gabriele Zoppoli, Michele Cea, Debora Soncini, Floriana Fruscione, Justine Rudner, Eva Moran, Irene Caffa, Davide Bedognetti, Giulia Motta, Riccardo Ghio, Fabio Ferrando, Alberto Ballestrero, Silvio Parodi, Claus Belka, Franco Patrone, Santina Bruzzone, Alessio Nencioni

1596 related Products with: Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells.

100 96T100.00 ug100uL1.00 flask5ug25mg2.5 mg0.1 ml4 Arrays/Slide

Related Pathways